David A. Siegel Avidity Biosciences, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 16,400 shares of RNA stock, worth $505,776. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,400

Previous 81,900 79.98%

Holding current value

$505,776

Previous $3.76 Million 87.34%

% of portfolio

0.0%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$29.08 - $52.5 $1.9 Million - $3.44 Million	-65,500 Reduced 79.98%	16,400 $476,000
Q3 2024 Nov 14, 2024	SELL	$37.21 - $48.14 $6.23 Million - $8.06 Million	-167,500 Reduced 67.16%	81,900 $3.76 Million
Q2 2024 Aug 14, 2024	SELL	$22.73 - $40.85 $4.65 Million - $8.35 Million	-204,500 Reduced 45.05%	249,400 $10.2 Million
Q1 2024 May 15, 2024	SELL	$9.16 - $25.52 $459,832 - $1.28 Million	-50,200 Reduced 9.96%	453,900 $11.6 Million
Q4 2023 Feb 14, 2024	SELL	$4.87 - $9.37 $171,911 - $330,761	-35,300 Reduced 6.54%	504,100 $4.56 Million
Q3 2023 Nov 14, 2023	BUY	$6.3 - $11.35 $1.21 Million - $2.18 Million	191,900 Added 55.22%	539,400 $3.44 Million
Q2 2023 Aug 14, 2023	BUY	$10.62 - $17.34 $2.19 Million - $3.58 Million	206,300 Added 146.1%	347,500 $3.85 Million
Q1 2023 May 15, 2023	BUY	$15.35 - $25.65 $1.3 Million - $2.16 Million	84,400 Added 148.59%	141,200 $2.17 Million
Q4 2022 Feb 14, 2023	BUY	$10.06 - $22.66 $571,408 - $1.29 Million	56,800 New	56,800 $1.26 Million

Others Institutions Holding RNA

# of Institutions

258

Shares Held

108M

Call Options Held

517K

Put Options Held

717K

View Full List

About Avidity Biosciences, Inc.

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $1.61B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

More about RNA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account